微信小陈
微信小章| 产品名称： | 803-15.6 |
|---|---|
| 商品货号： | TS212784 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with both native and denatured HIV-1 gp120 within the conserved C-terminal amino acid sequence residues 495-516. The antibody can be used for the purification of gp120 using a milder elution condition (pH4) than many other antibodies; it can be used in ELISA and Western Blot assays. |
| Storage Conditions： | liquid nitrgoen vapor phase |
| Derivation： | Animals were immunized with recombinant immunodeficiency virus 1 (HIV-1) gp120 (IIIB variant) purified from Baculovirus supernatant. Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human immunodeficiency virus 1 (HIV-1) gp120. |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human immunodeficiency virus 1 (HIV-1) gp120. |
| Comments： | Animals were immunized with recombinant immunodeficiency virus 1 (HIV-1) gp120 (IIIB variant) purified from Baculovirus supernatant. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The cell line was subcloned six times and adapted to growth in serum-free medium. The antibody reacts with both native and denatured HIV-1 gp120 within the conserved C-terminal amino acid sequence residues 495-516. The antibody can be used for the purification of gp120 using a milder elution condition (pH4) than many other antibodies; it can be used in ELISA and Western Blot assays. |
| Complete Growth Medium： | HB101 medium supplemented with 2 mM L-glutamine, 1.0 mM sodium pyruvate, 10 mM HEPES and 0.021 mM 2-mercaptoethanol
|
| Subculturing： | Cultures can be maintained by addition of fresh Medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL.xa0 Maintain cultures at a cell concentration between 1 x 105 andxa0 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | MR van Schravendijk |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Golden A, et al. Effect of promoters and signal sequences on the production of secreted HIV-1 gp120 protein in the baculovirus system. Protein Expr. Purif. 14: 8-12, 1998. PubMed: 9758745 Ferrer M, et al. Construction and characterization of a radio-iodinatable mutant of recombinant human CD4. J. Immunol. Methods 210: 215-225, 1997. PubMed: 9520304 Ferrer M, Harrison SC. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 73: 5795-5802, 1999. PubMed: 10364331 Ferrer M, et al. Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. J. Peptide Res. 54: 32-42, 1999. PubMed: 10448968 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |